The primary objectives of this study are to evaluate the effects of Tralesinidase Alfa (TA) on cognition
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
14
TA study drug is a sterile solution for ICV infusion.
Change from Baseline in Bayley Scales of Infant and Toddler Development, Third Edition, Cognition Domain (BSID-III-C) Raw Score
The BSID-III-C is a standardized tool that evaluates cognitive development in young children, capturing skills such as processing speed, problem solving, and play. Raw scores are used to sensitively measure individual change over time, independent of age. Assessments are administered by a trained, blinded rater and reviewed by a central blinded rater. The endpoint is the difference in mean change from baseline in BSID-III-C raw score between the tralesinidase alfa and control arms at Week 260
Time frame: Baseline to Week 260 (approximately 5 years)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.